We DesignWe apply our unique collective expertise to design small molecule therapeutics. BreakthroughWe push the leading edge to solve drug discovery’s big challenges. MedicinesWe strive to develop meaningful medicines for patients.
Over more than a decade of pioneering technologically-driven methods of drug discovery, Nimbus has used cutting-edge tools to make therapeutic progress against the most challenging of targets — successfully drugging the undruggable, mapping the uncrystallizable and advancing multiple innovative therapeutics to the clinic.
Chief People Officer
Senior Vice President, Head of Chemistry
Chief Business Officer
Chief Executive Officer
Senior Vice President, Head of Biology
Vice President, CMC
Chief Financial Officer
Vice President, Early Clinical Development
Chief Scientific Officer
Vice President, Clinical Operations
Chief Accounting Officer
Board of Directors
General Partner, Atlas VentureRead bio
General Partner, Lightstone VenturesRead bio
Principal, RA Capital ManagementRead bio
Partner, SR One Ltd.Read bio
Operating Partner , Havencrest Healthcare PartnersRead bio
Chairman and CEO, Kala PharmaceuticalsRead bio
Principal, BVF Partners L.P.Read bio
CEO, Nimbus TherapeuticsRead bio
President and CSO, Navitor PharmaceuticalsRead bio
Nimbus Therapeutics is backed by world-class life science investors, including those listed below and others. The company closed a $24 million Series A financing in June 2011, a $43 million Series B financing in March 2015, an additional $65 million in financing in June 2018, $60 million in financing in October 2020, and $105 million in financing in July 2021.